Experimental antitumor activity of BMY-28090, a new antitumor antibiotic

@article{Schurig2004ExperimentalAA,
  title={Experimental antitumor activity of BMY-28090, a new antitumor antibiotic},
  author={J. Schurig and W. T. Bradner and G. Basler and W. Rose},
  journal={Investigational New Drugs},
  year={2004},
  volume={7},
  pages={173-178}
}
SummaryBMY-28090 is a novel actinomycete fermentation derived antitumor agent. The cytotoxic effect of BMY-28090 was evaluated in two murine and eight human tumor cell lines in vitro. Following 72-hour exposures, BMY-28090 was cytotoxic for all of these cell lines with IC50 values of < 0.02 to 3.25 μg/ml. BMY-28090 was evaluated for in vivo antitumor activity in a variety of experimental murine tumor and human tumor xenograft models. Initial testing against the murine tumor models was performed… Expand

References

SHOWING 1-10 OF 10 REFERENCES
Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
A microtitre cytotoxicity assay useful for the discovery of fermentation-derived antitumor agents
Evaluation of platinol analogs using the M5076 murine sarcoma.
  • W. Rose
  • Medicine
  • Anticancer research
  • 1986
Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo
Growth and treatment of a human colon tumor cell line xenografted in the subrenal capsule (src) of irradiated mice
  • (Abstr) Proc Amer Assoc Cancer Res
  • 1986
BMY-28090 a new antitumor antibiotic related to chartreusin: Isolation, chemistry and activity
  • Abs 14th Int Congr Chemother:320,
  • 1985